Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IDELALISIB Cause Systemic inflammatory response syndrome? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Systemic inflammatory response syndrome have been filed in association with IDELALISIB (Zydelig). This represents 0.1% of all adverse event reports for IDELALISIB.

6
Reports of Systemic inflammatory response syndrome with IDELALISIB
0.1%
of all IDELALISIB reports
2
Deaths
5
Hospitalizations

How Dangerous Is Systemic inflammatory response syndrome From IDELALISIB?

Of the 6 reports, 2 (33.3%) resulted in death, 5 (83.3%) required hospitalization, and 1 (16.7%) were considered life-threatening.

Is Systemic inflammatory response syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IDELALISIB. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does IDELALISIB Cause?

Disease progression (1,204) Death (779) Diarrhoea (752) Off label use (548) Pneumonia (426) Pyrexia (371) Drug ineffective (294) Fatigue (284) Dehydration (242) Dyspnoea (206)

What Other Drugs Cause Systemic inflammatory response syndrome?

DOXORUBICIN (161) METHOTREXATE (158) CYCLOPHOSPHAMIDE (153) CYTARABINE (153) METHYLPREDNISOLONE (117) ADALIMUMAB (107) RITUXIMAB (106) PREDNISOLONE (99) VINCRISTINE (97) MYCOPHENOLATE MOFETIL (95)

Which IDELALISIB Alternatives Have Lower Systemic inflammatory response syndrome Risk?

IDELALISIB vs IDURSULFASE IDELALISIB vs IFOSFAMIDE IDELALISIB vs IGURATIMOD IDELALISIB vs ILOPERIDONE IDELALISIB vs ILOPROST

Related Pages

IDELALISIB Full Profile All Systemic inflammatory response syndrome Reports All Drugs Causing Systemic inflammatory response syndrome IDELALISIB Demographics